| Autor: |
Bernau K; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin., Leet JP; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin., Bruhn EM; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin., Tubbs AJ; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin., Zhu T; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin., Sandbo N; Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin. |
| Abstrakt: |
Extracellular matrix deposition characterizes idiopathic pulmonary fibrosis (IPF) and is orchestrated by myofibroblasts. The lung mesenchyme is an essential source of myofibroblasts in pulmonary fibrosis. Although the transcription factor serum response factor (SRF) has shown to be critical in the process of myofibroblast differentiation, its role in development of pulmonary fibrosis has not been determined in vivo. In this study, we observed that SRF expression localized to mesenchymal compartments, areas of dense fibrosis, and fibroblastic foci in human (IPF and normal) and bleomycin-treated mouse lungs. To determine the role of mesenchymal SRF in pulmonary fibrosis, we utilized a doxycycline-inducible, Tbx4 lung enhancer (Tbx4 LE )-driven Cre-recombinase to disrupt SRF expression in the lung mesenchyme in vivo. Doxycycline-treated Tbx4 LE -rtTA/TetO-Cre/tdTom/SRF f,f (and controls) were treated with a single intratracheal dose of bleomycin to induce pulmonary fibrosis and examined for lung mesenchymal expansion, pulmonary fibrosis, and inflammatory response. Bleomycin-treated Tbx4 LE -rtTA/TetO-Cre/tdTom/SRF f,f mice showed decreased numbers of Tbx4 LE -positive lung mesenchymal cells (LMCs) and collagen accumulation (via hydroxyproline assay) compared with controls. This effect was associated with SRF-null LMCs losing their proliferative and myofibroblast differentiation potential compared with SRF-positive controls. Together, these data demonstrate that SRF plays a critical role in LMC myofibroblast expansion during bleomycin-induced pulmonary fibrosis. This sets the stage for pharmacological strategies that specifically target SRF in the lung mesenchyme as a potential means of treating pulmonary fibrosis. |
